External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Roche and Genentech at

ILCA 2024

October 17 - October 19

Toronto, Canada

ilca.com

Add to calendar

Medical Materials

Agenda

Coming soon

12:00 PM

Duration 45mins Toronto, Canada

Depth of response and Duration of response are Associated with Overall survival in Patients with Unresectable Hepatocellular Carcinoma: Exploratory Analyses of IMbrave150

Kudo M, Yamashita T, Finn R S, Galle P R, Ducreux M, Cheng A, Tsuchiya K, Sakamoto N, Hige S, Take R, Yamada K, Asakawa T, Nakagawa Y, Ikeda M

Oncology | Gastric Cancer - Gastrointestinal Cancer

Add to calendar

02:50 PM

Duration 10mins presentation hall

Exploratory Efficacy and Safety Results in Patients with HCC With Main Trunk and/or Contralateral Portal Vein Invasion (Vp4) Treated with Atezolizumab + Bevacizumab vs. Sorafenib in the Global Phase III IMbrave150 Study

Li D, Galle P, Ducreux M, Cheng A-L, Reilly N, Nicholas A, Hernandez S, Ning M, Merle P, Salem R, Breder V, Finn RS

Oncology | Gastric Cancer - Gastrointestinal Cancer

Add to calendar

05:00 PM

Duration 1hr Toronto, Canada

Transforming Liver Cancer Treatment: From Today’s Innovation to Tomorrow’s Potential

Bruno Sangro, Angela Lamarca, Arndt Vogel, Gonzalo Sapisochin

Oncology | Liver Cancer

Add to calendar

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.